Kanazawa Tetsufumi, Glatt Stephen J, Kia-Keating Brett, Yoneda Hiroshi, Tsuang Ming T
Department of Psychiatry, Center for Behavioral Genomics, University of California, San Diego, California 92093, USA.
Psychiatr Genet. 2007 Jun;17(3):165-70. doi: 10.1097/YPG.0b013e32801da2e2.
A long-term controversy exists on whether or not major psychotic disorders can be discretely divided into two groups, for example, schizophrenia and bipolar disorder. Many genes and polymorphisms have been studied for a role in both disorders, including the Val66Met (also known as rs 6265 or G196A) variant of brain-derived neurotrophic factor (BDNF). Many case-control association studies have been performed to see if BDNF could serve as a useful clinical diagnostic biomarker for schizophrenia or bipolar disorder, but results have been equivocal.
To determine, by meta-analysis, if the Val66Met polymorphism of BDNF influences risk for either schizophrenia, bipolar disorder, or both.
We searched Pubmed, Medline, and PsycInfo using keywords including Val66Met, Rs6265, G196A, BDNF, schizophrenia, and bipolar disorder. A total of 13 studies for schizophrenia and 11 studies for bipolar disorder were combined by random-effects meta-analysis.
The pooled results from the schizophrenia sample (2955 patients; 4035 controls) and the bipolar disorder sample (3143 patients; 6347 controls) indicated lack of significance with either of the two psychoses, with pooled odds ratios of 1.00 (P=0.944) and 0.95 (P=0.161), respectively.
Although there are some limitations on the study, our results indicate there is a lack of association between the Val66Met polymorphism and either of the two psychoses. A larger sample size, and evaluation of more single-nucleotide polymorphisms are needed to obtain more robust and conclusive findings regarding the relationship between the BDNF gene and psychosis.
关于严重精神障碍是否可明确分为两组，例如精神分裂症和双相情感障碍，长期以来存在争议。许多基因和多态性已被研究是否在这两种疾病中起作用，包括脑源性神经营养因子（BDNF）的Val66Met（也称为rs 6265或G196A）变体。已经进行了许多病例对照关联研究，以确定BDNF是否可作为精神分裂症或双相情感障碍的有用临床诊断生物标志物，但结果并不明确。
通过荟萃分析确定BDNF的Val66Met多态性是否影响精神分裂症、双相情感障碍或两者的风险。
我们使用包括Val66Met、Rs6265、G196A、BDNF、精神分裂症和双相情感障碍等关键词在PubMed、Medline和PsycInfo中进行搜索。通过随机效应荟萃分析合并了13项关于精神分裂症的研究和11项关于双相情感障碍的研究。
精神分裂症样本（2955例患者；4035例对照）和双相情感障碍样本（3143例患者；6347例对照）的汇总结果表明，与这两种精神病中的任何一种均无显著关联，汇总比值比分别为1.00（P=0.944）和0.95（P=0.161）。
尽管该研究存在一些局限性，但我们的结果表明Val66Met多态性与这两种精神病中的任何一种均无关联。需要更大的样本量和对更多单核苷酸多态性的评估，以获得关于BDNF基因与精神病之间关系的更可靠和确凿的发现。
